Rare lung cancer under the microscope: what can past cases teach us?
NCT ID NCT07459127
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is gathering information from medical records of 150 people with a rare lung cancer called NUT carcinoma. Researchers want to see what treatments patients received in real life and how they fared over time. No new treatments are being tested; instead, the goal is to learn more about this cancer to help design better studies in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide valuable insights into how lung NUT carcinoma is currently treated and what outcomes patients experience, potentially guiding future research.
- What could go wrong
- This is an observational study that does not test any new treatment. It only looks back at existing medical records, so it cannot prove what works best. Results may vary across hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
150 people
The number who actually took part.
- Started
-
Jan 2023
- Expected to finish
-
May 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with pulmonary (lung) NUT carcinoma identified retrospectively from participating hospitals using pathology records, with clinical, pathologic, and imaging data abstracted from existing medical records and de-identified for analysis.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Pathologically confirmed pulmonary (lung) NUT carcinoma. * Evidence of NUT immunohistochemistry (IHC) positivity and/or NUTM1 rearrangement/fusion, per local pathology report. * Diagnosed and/or treated at a participating hospital during the study period. * Availability of sufficient medical record data to abstract key baseline characteristics, treatments, and outcomes. Exclusion Criteria: * Primary tumor site not in the lung. * Records insufficient to confirm the diagnosis of pulmonary NUT carcinoma. * No follow-up or outcome information available after diagnosis (insufficient for survival/outcome assessment).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nut carcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chongqing University Three Gorges Hospital
Chongqing, Chongqing Municipality, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.